Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag^® payloads across multiple ADCs designed to address difficult-to-treat diseases

Read more at globenewswire.com